Enveric Biosciences, Inc. (ENVB)
After hours:
| Previous close | 0.9200 |
| Open | 0.8990 |
| Bid | 0.8714 x 100 |
| Ask | 0.9438 x 100 |
| Day's range | 0.8765 - 0.9400 |
| 52-week range | 0.6490 - 6.9800 |
| Volume | |
| Avg. volume | 4,727,666 |
| Market cap | 6.492M |
| Beta (5Y monthly) | 0.55 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -8.0900 |
| Earnings date | 13 May 2024 - 17 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 23 Apr 2008 |
| 1y target est | 8.00 |
Business WireEnveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids
CAMBRIDGE, Mass., May 08, 2024--Enveric Biosciences, Inc (NASDAQ: ENVB), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that it has signed a non-binding term sheet with an undisclosed biotechnology development and commercialization company ("Licensee") to exclusively out-license two patent families of Methods for Treating Breast Cancer and Other Cancers f
Business WireEnveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023
CAMBRIDGE, Mass., March 26, 2024--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided a corporate update and reported financial results for the fourth quarter of 2023 and fiscal year ended December 31, 2023.
Business WireEnveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease
CAMBRIDGE, Mass., March 19, 2024--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, is pleased to announce that it has signed two non-binding term sheets with an undisclosed biotechnology company to pursue the out-licensing of cannabinoid-COX-2 conjugate compounds for both pharmaceutical and non-pharmaceutical
